Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: There is emerging data to suggest that the optimal use of angiogenesis inhibitors
may be in combination with chemotherapy. The optimal use of atrasentan may be in combination
with chemotherapy in women with relapsed and refractory ovarian cancer,fallopian tube cancer,
and peritoneal serous papillary adenocarcinoma. Due to its manageable toxicity profile, ease
of administration, and activity in both platinum sensitive as well as platinum-resistant
patients, Doxil has become the 2nd-line treatment of choice for women with advanced stage
ovarian cancer that has progressed following 1st-line platinum/taxane therapy.
PURPOSE: To determine if a treatment combination of atrasentan + Doxil is an effective 2nd
line treatment in patients with recurrent ovarian cancer, fallopian tube cancer, or
peritoneal cancer.